CADL plunges 38% as prostate cancer filing slips to 2027
Asianet Newsable (Stocktwits) · · AI-summarised by FinFlash
Candel Therapeutics shares fell 38% in after-hours trading after the biotech said it now expects to file for FDA approval of its prostate cancer therapy aglatimagene besadenovec in mid-2027, later than its earlier fourth-quarter 2026 target, citing assay refinements and continuing FDA dialogue. The stock had already closed down 9% at $8.39. Third-quarter net loss widened to $21.9 million from The delay pushes back Candel's first potential revenue and weighs on small-cap oncology sentiment. Watch for clarity from FDA talks on the assay requirements. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context